Latest On Santen Pharmaceutical Co., Ltd (SNPHF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-10-06 20:17 EST | News | Santen's dry eye therapy Cationorm gets approval in Canada | N/A |  |
| 2022-08-07 15:27 EST | News | Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-02-11 13:35 EST | News | Santen Pharmaceutical Co., Ltd. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-12-07 22:46 EST | News | Aerie inks licensing deal for Rhopressa and Rocklatan in Europe and several other regions | N/A | |
| 2021-11-11 18:00 EST | News | Santen Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-11-09 22:43 EST | News | Santen Pharmaceutical reports 1H results | N/A | |
| 2021-08-09 19:43 EST | News | Santen Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation | N/A | |
| 2021-03-30 06:08 EST | Dividend | A dividend of $14 has been announced on May 8, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral | |
| 2021-02-10 21:34 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-05 05:32 EST | Earnings Estimate | An EPS average of $0.18 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2020-11-26 23:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-09 22:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-27 07:28 EST | News | FDA accepts Santen application for severe allergic eye disease | N/A | |
| 2020-09-26 15:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 02:33 EST | Earnings Estimate | An EPS average of $0.14 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-08-07 02:33 EST | Earnings Estimate | An EPS average of $0.88 is estimated for the 2022 year. | Buy | |
| 2020-08-07 02:33 EST | Earnings Estimate | An EPS average of $0.74 is estimated for the 2021 year. | Buy | |
| 2020-08-07 02:33 EST | Earnings Estimate | An EPS average of $0.15 is estimated for the quarter ending on December 31, 2020. | N/A | |
| 2020-08-06 22:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-09 22:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 07:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-30 06:12 EST | Dividend | A dividend of $14 has been announced on May 9, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020. | Neutral | |
| 2020-03-25 22:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-03 10:36 EST | Stock Split | A stock split has occured on Mar 27, 2015 with a split factor of 5:1. | Neutral | |
| 2020-02-28 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:46 EST | Financials | Company financials have been released. | Neutral | |
About Santen Pharmaceutical Co., Ltd (SNPHF):
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase 3 clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase 2/3 clinical trial in Japan, as well as is in Phase 3 in Asia; and MD-16 for the treatment of cataract. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
General
- Name Santen Pharmaceutical Co., Ltd
- Symbol SNPHF
- Type Common Stock
- Exchange OTCGREY
- Currency USD
- Country USA
- Full Time Employees 4,108
- Last Split Factor5:1
- Last Split Date2015-03-27
- Fiscal Year EndMarch
- Web URLhttp://www.santen.com
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $0.69
- Next Year EPS Estimate $0.77
- Next Quarter EPS Estimate $0.06
- Profit Margin 10%
- Return on Assets 6%
- Return on Equity 7%
- Revenue Per Share $0
- Gross Profit 146.72 billion
- Quarterly Earnings Growth -1.1%
View More
ESG Rating
Highlights
- Market Capitalization 5.52 billion
- PEG Ratio 20398.6
View More
Share Statistics
- Shares Outstanding 407.09 million
- Shares Float 390.22 million
- % Held by Insiders 389%
- % Held by Institutions 44.94%
View More
Technicals
- Beta 0.35
- 52 Week High $20.15
- 52 Week Low $13.2
- 50 Day Moving Average 15.08
- 200 Day Moving Average 17.11
View More
Dividends
- Forward Annual Dividend Yield 0.71%
- Payout Ratio 39%
- Dividend Date 2018-06-27
- ExDividend Date N/A
- Dividend Yield 0%
View More
Santen Pharmaceutical Co., Ltd (SNPHF) Dividend Calendar:
SNPHF's last dividend payment was made to shareholders on June 27, 2018.
Santen Pharmaceutical Co., Ltd pays out 39% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Santen Pharmaceutical Co., Ltd (SNPHF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.17 | $0.11 | 54.55% |
| 2020-09-30 | 2020-12-31 | $N/A | $0.18 | $15.00 | -98.82% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.18 | $16.90 | -98.93% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.14 | ||
| 2019-12-31 | 2020-03-31 | $585.05 million | $0.08 | ||
| 2019-09-30 | 2019-12-31 | $551.8 million | $0.16 | ||
| 2019-06-30 | 2019-09-30 | $545.31 million | $0.16 | ||
| 2019-03-31 | 2019-06-30 | $546.15 million | $0.15 | ||
| 2018-12-31 | 2019-03-31 | $537.22 million | $0.19 | ||
| 2018-09-30 | 2018-12-31 | $507.89 million | $0.20 | ||
| 2018-06-30 | 2018-09-30 | $509.34 million | $0.16 | $22.60 | -99.28% |
| 2018-03-31 | 2018-06-30 | $532.13 million | $0.15 | ||
| 2017-12-31 | 2018-03-31 | $513.22 million | $0.18 | ||
| 2017-09-30 | 2017-12-31 | $486.2 million | $0.26 | ||
| 2017-06-30 | 2017-09-30 | $55.95 billion | $0.14 | $19.70 | -99.31% |
| 2017-03-31 | 2017-06-30 | $48.43 billion | $0.20 | ||
| 2016-12-31 | 2017-03-31 | $52.84 billion | $0.07 | ||
| 2016-09-30 | 2016-12-31 | $0.15 | |||
| 2016-06-30 | 2016-09-30 | $0.13 | |||
| 2016-03-31 | 2016-06-30 | $0.17 | |||
| 2015-12-31 | 2016-03-31 | $0.07 | |||
| 2015-09-30 | 2015-12-31 | $0.12 | |||
| 2015-06-30 | 2015-09-30 | $0.73 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $0.15 | $10.54 | -98.59% | |
| 2014-12-31 | 2015-03-31 | $0.16 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $0.14 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.12 | $10.18 | -98.84% | |
| 2014-03-31 | 2014-06-30 | $0.09 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.04 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.15 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.08 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.14 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.06 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.14 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.14 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.12 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.07 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.14 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.13 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.16 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.19 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.16 | $0.00 |
Santen Pharmaceutical Co., Ltd (SNPHF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 52.85 million |
| Income Before Tax | N/A | N/A | N/A | N/A | 97.18 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 178.72 million |
| Gross Profit | N/A | N/A | N/A | N/A | 345.19 million |
| Ebit | N/A | N/A | N/A | N/A | 91.43 million |
| Operating Income | N/A | N/A | N/A | N/A | 91.43 million |
| Income Tax Expense | 1.36 billion | 2.42 billion | 2.24 billion | 1.69 billion | 31.36 million |
| Total Revenue | N/A | N/A | N/A | N/A | 585.05 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 239.86 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 5.74 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 65.81 million |
| Net Income Applicable to Common Shares | 7.3 billion | 7.63 billion | 6.19 billion | 3.32 billion | 65.85 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | 8.44 million | 7.31 million |
| Change to Liabilities | -1.61 billion | 1.21 billion | 3.36 billion | -4.35 million | 37.2 million |
| Total Cash Flow from Investing Activities | -34.17 billion | -10.56 billion | -1.65 billion | -14.91 million | -5.12 million |
| Net Borrowings | 35 million | 113 million | 60 million | 3.03 million | 5.44 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -51.11 million | -2.03 million |
| Change to Operating Activities | 1.24 billion | 295 million | 1.11 billion | 58.08 million | 19.33 million |
| Change in Cash | N/A | N/A | N/A | -21.87 million | 158.89 million |
| Total Cash from Operating Activities | 10.98 billion | 7.45 billion | 12.59 billion | 34.74 million | 171.99 million |
| Depreciation | N/A | N/A | N/A | 38.13 million | 37.75 million |
| Other Cash Flow from Investing Activities | -6 million | -8 million | -10 million | -82853.86 | 9.03 million |
| Change to Inventory | N/A | N/A | N/A | 9.22 million | -7.43 million |
| Change to Account Receivables | N/A | N/A | N/A | -76.46 million | 33.38 million |
| Other Cash Flow from Financing Activities | -722 million | -605 million | -1.18 billion | -6.94 million | -6.73 million |
| Change to Net Income | -848 million | -5.99 billion | 5.19 billion | -55.7 million | -10.59 million |
| Capital Expenditures | N/A | N/A | N/A | 17.13 million | 14.9 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 956.49 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 2.78 billion |
| Other Current Liabilities | 31.83 billion | 33.23 billion | N/A | N/A | 260.77 million |
| Total Assets | N/A | N/A | N/A | N/A | 3.75 billion |
| Common Stock | 8.45 billion | 8.41 billion | 8.41 billion | 8.37 billion | 76.37 million |
| Other Current Assets | 6.15 billion | 6.33 billion | N/A | N/A | 41.95 million |
| Retained Earnings | 284.56 billion | 281.64 billion | 274.02 billion | 273.42 billion | 2.48 billion |
| Other Liabilities | 36.34 billion | 38.66 billion | 41.43 billion | 38.61 billion | 413.76 million |
| Other Assets | 2.8 billion | 2.45 billion | 2.3 billion | 2.1 billion | 20.43 million |
| Cash | N/A | N/A | N/A | N/A | 760.37 million |
| Total Current Liabilities | 62.02 billion | 65.73 billion | N/A | N/A | 542.73 million |
| Other Stockholder Equity | 14.31 billion | 18.18 billion | 15.96 billion | 13.36 billion | 150.93 million |
| Property, Plant & Equipment | 35.65 billion | 36.22 billion | 35.74 billion | 35.6 billion | 360.98 million |
| Total Current Assets | 183.89 billion | 187.08 billion | N/A | N/A | 1.91 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 316.48 million |
| Net Tangible Assets | 164.44 billion | 168.04 billion | 182.47 billion | 183.02 billion | 1.64 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 37.91 billion | 40.11 billion | N/A | N/A | 304.14 million |
| Accounts Payable | 30.19 billion | 32.51 billion | N/A | N/A | 281.96 million |
Santen Pharmaceutical Co., Ltd (SNPHF) Chart:
Santen Pharmaceutical Co., Ltd (SNPHF) News:
Below you will find a list of latest news for Santen Pharmaceutical Co., Ltd (SNPHF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Santen Pharmaceutical Co., Ltd (SNPHF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Santen Pharmaceutical Co., Ltd (SNPHF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2010-09-10 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000101915510000330/0001019155-10-000330-index.htm |
| 2015-03-30 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1501108/000101915515000133/0001019155-15-000133-index.htm |
| 2013-01-30 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000119380513000146/0001193805-13-000146-index.htm |
| 2013-02-01 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000119380513000182/0001193805-13-000182-index.htm |
| 2015-03-24 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1501108/000119380515000425/0001193805-15-000425-index.htm |
| 2015-04-15 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1501108/000119380515000577/0001193805-15-000577-index.htm |
| 2016-03-07 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000119380516002774/0001193805-16-002774-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1501108/000119380517002951/0001193805-17-002951-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000119380519001509/0001193805-19-001509-index.htm |
| 2014-10-16 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1501108/000157104914005155/0001571049-14-005155-index.htm |